

Table S2. Clinical characteristics and association with progression-free survival of the 194 NSCLC patients.

| Characteristic | PFS | | | | | | | | |
|--|-----|--------|----------|------------|------------------|--------------------|----------------------|-----------|------------------|
| | N | Events | MST (mo) | IC95% | Log-Rank p-value | Reference Category | Univariate Cox Model | | |
| | | | | | | | HR | IC95% | p-value |
| Gender | | | | | | | | | |
| Female | 53 | 43 | 17.6 | 12.9-30.0 | 0.050 | Female | 1.403 | 0.99-1.99 | 0.0558 |
| Male | 141 | 127 | 11.9 | 9.87-16.1 | | | | | |
| Family history | | | | | | | | | |
| Yes | 102 | 93 | 15.6 | 11.4-19.4 | 0.200 | | | | |
| No | 89 | 75 | 12.1 | 10.2-16.8 | | | | | |
| Previous lung disease | | | | | | | | | |
| Yes | 55 | 45 | 17.6 | 12.7-24.7 | 0.040 | Yes | 1.422 | 1.01-2.01 | 0.0452 |
| No | 139 | 125 | 12.3 | 10.5-16.7 | | | | | |
| Smoking status | | | | | | | | | |
| Current-Smokers | 92 | 81 | 13.4 | 10.30-19.2 | 0.900 | | | | |
| Former-smokers | 75 | 64 | 13.2 | 9.07-18.7 | | | | | |
| Non-smokers | 27 | 25 | 15.6 | 12.03-20.0 | | | | | |
| Alcoholic status | | | | | | | | | |
| Current-Drinkers | 33 | 30 | 9.17 | 6.7-20.9 | 0.020 | Non-drinkers | 1.508 | 1.00-2.27 | 0.0485 |
| Former-Drinkers | 4 | 4 | 7.82 | 5.1-NR | | | 2.886 | 1.05-7.95 | 0.0403 |
| Non-drinkers | 124 | 105 | 17.07 | 12.9-20.2 | | | 1 | | |
| Age at NSCLC diagnosis | | | | | | | | | |
| ≤60 | 85 | 74 | 11.9 | 10.2-17.1 | 1.000 | | | | |
| >60 | 109 | 96 | 15.8 | 12.8-19.2 | | | | | |
| BMI | | | | | | | | | |
| <24 | 31 | 26 | 24.5 | 17.6-51.9 | 0.200 | | | | |
| >24 | 83 | 70 | 12.9 | 10.3-18.7 | | | | | |
| Histology | | | | | | | | | |
| Adenocarcinoma | 119 | 107 | 14.2 | 11.4-17.1 | 0.200 | | | | |
| Squamous cell carcinoma | 72 | 61 | 12.9 | 10.0-24.7 | | | | | |
| Tumor stage | | | | | | | | | |
| I, II and IIIA | 63 | 44 | 29.4 | 24.47-86.1 | <0.001 | I, II and IIIA | 3.026 | 2.11-4.34 | <0.001 |
| IIIB and IV | 130 | 125 | 10.6 | 9.07-12.8 | | | | | |
| First course of treatment | | | | | | | | | |
| Surgery | 48 | 29 | 59.0 | 25.6-NR | <0.001 | Surgery | 1 | | |
| Chemoradiotherapy | 121 | 118 | 10.2 | 7.7-12.9 | | | 3.964 | 2.58-6.08 | <0.001 |
| Targeted therapy | 25 | 23 | 15.8 | 12.0-21.8 | | | 3.233 | 1.82-5.73 | <0.001 |
| First course of treatment (divided by surgery) | | | | | | | | | |
| Surgery | 48 | 29 | 59.0 | 25.6-NR | <0.001 | Surgery | 3.838 | 2.51-5.87 | <0.001 |
| No surgery | 146 | 141 | 10.9 | 10.0-13.2 | | | | | |

MST: median survival time (months)

NR: not reached

HR: hazard ratio

IC95%: 95% confidence interval